Congenital hyperinsulinism (CHI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

The incidence of cases of Congenital hyperinsulinism (CHI) ranges between 1.72 to 2.45 cases per 48,000 live birth in the USA and the EU5 incidence cases range between 1.55 to 2.1 cases per 30,000 live birth. the overall prevalence cases ranges between 11,500 to 12,500 cases in 2020

Read more:- Congenital hyperinsulinism (CHI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Congenital-hyperinsulinism-CHI-forecast

Comprehensive insight on patient segmentation based on age, sex, Histology (Focal, Diffuse), Phenotype (diazoxide-responsive and diazoxide non-responsive), biomarker (HADH, KATP-HI, ABCC8, KCNJ11, HNF1A, GCK, SLC16A1, GLUD1, and Others), clinical characteristics (Consanguinity, Family history of CHI, Blood glucose, Se-rum insulin, and Hyperammonaemia), Signs & Symptoms (neonatal period, During infancy and childhood, and diazoxide-responsive), Clinical Manifestations, Treatment types (supportive therapy) has been provided into the epidemiology section of the Congenital hyperinsulinism (CHI) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

CI IMAGE

In terms of pharmacologic therapies, there are few drug candidates are in Phase III, II, I, and pre-clinical stages of development. Key assets among these are dasiglucagon from Zealand Pharma, octreotide, LAR from Novartis, XOMA-358 from Xoma, RZ358 from Rezolute, Avexitide from Egerbio, and HM-15136 from Han-mi Pharmaceuticals. The launch of key assets will positively impact the overall market from 2020 to 2030 in 8 MM countries. Also, mostly all the molecules have been granted orphan drug designation from FDA and EMA. In January 2020, the U.S. Food and Drug Administration (FDA) approved Zealand’s Investigational New Drug (IND) application for the initiation of two Phase III clinical trials of dasiglucagon in CHI.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-
Leukocyte Adhesion Deficiency Type II – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Aspartylglucosaminuria (AGU) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Neonatal Encephalopathy – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Small Cell Lung Cancer (SCLC) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Hereditary angioedema (HAE) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Congenital hyperinsulinism (CHI), Congenital hyperinsulinism (CHI) market outlook report, Congenital hyperinsulinism (CHI) competitive landscape, Congenital hyperinsulinism (CHI) market forecast